+862152810135 contact@jumopartners.com

Summary : New Measures on the Supervision and Administration of Medical Devices Trading 2022

by | May 9, 2022 | Press Follow up, Uncategorized

A new article was released by CMS on April 28th about this topic, and this very technical and long article requires 10 minutes to read it, if you are comfortable with all the terms.

In order to save your time and offer a more synthetic vision, we have prepared a summary of this article.

Time to read it : 90 seconds.


Here is the original source : Article / PDF

Here is our summary :

1. Stricter Quality Management Requirements

As of today, NMPA together with the National Heath Commission and the National Healthcare Security Administration has published the lists of two batches of medical products that are subject to unique device identification system. The list includes all of the Class-III medical devices as well as all stock-in inspection record system for each product. Sales records of medical devices must include the name, model, specification, registration certificate number or filing number, quantity, unit price, and amount. If there is no validity period, they shall be kept for not less than 5 years. Article 41 of the Measures provides that medical device trading enterprises shall assist medical device registrants and filing entities to carry out adverse event monitoring.

2. Adjustment in Formalities for License or Record-Filing

  • Exemption from record-filing for Class II medical devices whose product safety and effectiveness are not affected by distribution process; 
  • The NMPA has already published a list of products that fall into this exemption category; 
  • Re-registration of Class III Medical Devices Trading License; the applicant shall file a re-registration application between 90 working days and 30 working days prior to the expiration of the validity period of the license. 

3. Stricter Supervision Measures

Article 47 of the Measures provides that drug administrative authorities shall implement a classification and grading management system according to the quality management of medical device trading enterprises. The Measures also provide that if traded medical devices cause harm to human body or it is proven that it may endanger human health, they may suspend import, trading and use, and issue safety warning information.


4. Heavier Legal Liabilities

The Measures intensify the punishment on those acts specifically regulated under the Measures. If a medical device trading enterprise fails to submit its annual self-inspection report of the quality management system as required, or violates the provisions of these Measures, drug administrative authorities shall order corrections within a time limit. If harmful consequences are caused, a fine of not less than 100,000 RMB but not more than 200,00 RMB may be imposed.

Medical devices trading enterprises should follow the new requirements contained in the Measures to achieve full compliance. Drug administrative authorities at the city level (with districts) shall establish and update the credit files of medical device trading enterprises within their jurisdiction in a timely manner.

Who is behind this summary ?

Anthony Zhang

Anthony Zhang

Account Manager

Beyond his function of Account Manager, Anthony spends part of  his time following up press content about trends, legal changes, and anything related to healthcare.


We are totally aware that some steps in your project of expanding your business to China might need to be further explained.

Jumo Partners is there to answer your questions and concerns.

Book your appointment

The spontaneity of a live discussion helps you to understand and answer promptly your questions.
A quick discussion is the most efficient way to talk about your project and your needs in order to define the best strategy to develop your company in China.

Contact us now and schedule your call with our team!

A propos de JUMO

JUMO, accélérateur en percées de marchés étrangers, est expert dans l'exploitation des opportunités de marchés pour s'installer et développer les sociétés de la santé en Chine.

Notre équipe aide votre entreprise à se développer de manière durable. Comprendre, concevoir, planifier, communiquer et vendre dans les marchés étranger pour vous, et avec vous.


Toutes les opinions exposées dans les interviews et témoignages impliquent uniquement l'intervenant.


208, Wending Road Room A-520
200030 Shanghai